摘要
目的探讨同型半胱氨酸(homocysteine,HCY)、血清胱抑素C(cystatin C,Cys-C)及β2-微球蛋白(β2-microglobulin,β2-MG)联合检测在慢性肾脏病(chronic kidney disease,CKD)患者诊断的应用价值。方法选取2019年3月至2019年11月在我院收治的214例CKD患者作为病例组,同时选取同期30位健康者作为对照组,分别检测各组血清HCY、Cys-C、β2-MG水平及传统肾功能(Scr、Urea)水平,分析各项指标间的关系,并采用受试者工作特征曲线(ROC曲线)分析HCY、Cys-C、β2-MG联合检测对诊断CKD的价值。结果①病例组与对照组比较,血清Cys-C、HCY及Scr水平从A组开始升高,β2-MG和Urea水平从B组和C组开始升高,差异有统计学意义(P﹤0.05)。②HCY、Cys-C、β2-MG与传统肾功Scr、Urea及eGFR相关性系数大小关系为Cys-C>β2-MG>HCY。③对CKD患者的诊断价值,血清HCY+CysC+β2-MG联合检测ROC曲线下面积最大为0.979,各项指标中以HCY+CysC+β2-MG联合检测对临床诊断效能最高(P﹤0.05)。结论血清HCY、Cys-C和β2-MG可作为早期肾功能损害的敏感指标,三者联合检测可提高早期诊断肾损害的灵敏度,为临床在CKD患者诊疗中提供重要指导价值。
Objective To explore the clinical value of homocysteine(HCY),serum cystatinC(cystatinC)andβ2-microglobulin(β2-MG)in the diagnosis of chronic kidney disease(CKD).Methods Selection in March 2019 to November 2019 in our hospital 214 cases patients with chronic kidney disease(CKD)as a group,and 30 healthy subjects as control group during this period,the group was detected in serum HCY,Cys-C,β2-MG level and traditional kidney(Scr and Urea)level,analysis the relationship between the indicators,and using the receiver-operating characteristic curve(ROC curve)analysis of HCY,Cys-C,β2-MG joint detection of the value of diagnosis of chronic kidney disease(CKD).Results Compared with the control group,serum levels of cys-c,HCY and Scr in the case group increased from group A,and levels ofβ2-MG and Urea increased from group B and C,with A statistically significant difference(P<0.05).The correlation coefficients of HCY,Cys-C andβ2-MG with traditional renal function Scr,Urea and eGFR were Cys-C>β2-MG>HCY.For the diagnosis of CKD patients,the maximum area under the ROC curve of serum HCY+CysC+β2-MG combined test was 0.979,among which HCY+CysC+β2-MG combined test had the highest clinical diagnosis efficiency(P<0.05).Conclusion Serum HCY,Cys-C andβ2-MG can be used as sensitive indicators of early renal impairment,and combined detection of the three can improve the sensitivity of early diagnosis of renal impairment,providing important guiding value for clinical diagnosis and treatment of patients with CKD.
作者
李卫彬
农雪凤
钟丽萍
冯耀华
卢珮
黄伟
黄培胜
LI Weibin;NONG Xuefeng;ZHONG Liping;FENG Yaohua;LU Pei;HUANG Wei;HUANG Peisheng(Clinical Laboratory of the People’s Hospital of Chongzuo,Chongzuo 532200,China)
出处
《标记免疫分析与临床》
CAS
2020年第4期661-664,682,共5页
Labeled Immunoassays and Clinical Medicine
